Combination therapy with exenatide decreases the dapagliflozin‐induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial

AIMS: Sodium‐glucose cotransporter‐2 inhibitors induce less weight loss than expected. This may be explained by sodium‐glucose cotransporter‐2 inhibitor‐induced alterations in central reward‐ and satiety circuits, leading to increased appetite and food intake. Glucagon‐like peptide‐1 receptor agonis...

Descripción completa

Detalles Bibliográficos
Autores principales: van Ruiten, Charlotte C., Veltman, Dick J., Wijdeveld, Madelief, ten Kulve, Jennifer S, Kramer, Mark H. H., Nieuwdorp, Max, IJzerman, Richard G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546212/
https://www.ncbi.nlm.nih.gov/pubmed/35491524
http://dx.doi.org/10.1111/dom.14732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546212/
https://www.ncbi.nlm.nih.gov/pubmed/35491524
http://dx.doi.org/10.1111/dom.14732

Ejemplares similares